256 related articles for article (PubMed ID: 33472910)
61. ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
[TBL] [Abstract][Full Text] [Related]
62. Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E; Schram AM; Kulick A; Misale S; Won HH; Yaeger R; Razavi P; Ptashkin R; Hechtman JF; Toska E; Cownie J; Somwar R; Shifman S; Mattar M; Selçuklu SD; Samoila A; Guzman S; Tuch BB; Ebata K; de Stanchina E; Nagy RJ; Lanman RB; Houck-Loomis B; Patel JA; Berger MF; Ladanyi M; Hyman DM; Drilon A; Scaltriti M
Nat Med; 2019 Sep; 25(9):1422-1427. PubMed ID: 31406350
[TBL] [Abstract][Full Text] [Related]
63. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
64. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
[TBL] [Abstract][Full Text] [Related]
65. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
66. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
Tran KA; Cheng MY; Mitra A; Ogawa H; Shi VY; Olney LP; Kloxin AM; Maverakis E
Drug Des Devel Ther; 2016; 10():43-52. PubMed ID: 26730180
[TBL] [Abstract][Full Text] [Related]
67. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
68. Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.
Sorokin AV; Kanikarla Marie P; Bitner L; Syed M; Woods M; Manyam G; Kwong LN; Johnson B; Morris VK; Jones P; Menter DG; Lee MS; Kopetz S
Cancer Res; 2022 Sep; 82(18):3335-3344. PubMed ID: 35913398
[TBL] [Abstract][Full Text] [Related]
69. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
70. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
71. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
72. Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis.
Rezaeian AH; Inuzuka H; Wei W
Adv Protein Chem Struct Biol; 2023; 135():179-201. PubMed ID: 37061331
[TBL] [Abstract][Full Text] [Related]
73. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.
Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J
Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951
[TBL] [Abstract][Full Text] [Related]
74. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
[TBL] [Abstract][Full Text] [Related]
75. Combined BRAF, EGFR, and MEK Inhibition in Patients with
Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
[TBL] [Abstract][Full Text] [Related]
76. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
77. Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors.
Kato S; Porter R; Okamura R; Lee S; Zelichov O; Tarcic G; Vidne M; Kurzrock R
Eur J Cancer; 2021 May; 149():184-192. PubMed ID: 33865203
[TBL] [Abstract][Full Text] [Related]
78. Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling.
Li D; Miermont AM; Sable R; Quadri HS; Mathews Griner LA; Martin SE; Odzorig T; De S; Ferrer M; Powers AS; Hewitt SM; Rudloff U
Mol Cancer Res; 2023 Apr; 21(4):316-331. PubMed ID: 36790955
[TBL] [Abstract][Full Text] [Related]
79. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
80. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
